Clinical
Manifestations
Treatment
of specific manifestations of HIV infection and AIDS in the person with
advanced disease targets specific symptoms.
Patients with HIV/AIDS experience a number of
symptoms related to the disease as well as the effects of treatment. Nurses
need to understand the causes, signs and symptoms, and inter-ventions to
enhance the quality of life of patients with HIV across the illness trajectory
(Ropka & Williams, 1998; Sherman, 1999). The clinical manifestations of
HIV/AIDS are widespread and may affect virtually any organ system. Diseases
associated with HIV infection and AIDS result from infections, malignancies, or
the
direct effect of HIV on body tissues. Symptom assessment tools developed for
research purposes could be useful in clinical practice to assess symptom
intensity and severity (Holzemer, Henry, Nokes, et al., 1999; Nokes, Wheeler
& Kendrew, 1994; Nokes & Bakken, 2002).
Shortness of breath, dyspnea (labored
breathing), cough, chest pain, and fever are associated with various OIs, such
as those caused by Pneumocystis carinii,
Mycobacterium avium-intracellulare, CMV, and Legionella species. The most common infection in people with AIDS
is Pneumocystis carinii pneumonia
(PCP), one of the first OIs described in association with AIDS.
PCP. PCP
is the most common OI resulting in an AIDS diagnosis.Without prophylactic
therapy (discussed below), PCP will de-velop in 80% of all HIV-infected
individuals. P. carinii was
orig-inally classified as a protozoan; however, studies and analysis of its
ribosomal RNA structure suggest that it is a fungus. Its structure and
antimicrobial sensitivity are very different from other disease-causing fungi. P. carinii causes disease only in
immunocompro-mised hosts, invading and proliferating within the pulmonary
alveoli with resultant consolidation of the pulmonary parenchyma.
The
clinical presentation of PCP in HIV infection is generally less acute than in
people who are immunosuppressed as a result of other conditions. The time
between the onset of symptoms and the actual documentation of disease may be
weeks to months. Patients with AIDS initially develop nonspecific signs and
symp-toms, such as nonproductive cough, fever, chills, shortness of breath,
dyspnea, and occasionally chest pain. PCP may be pres-ent despite the absence
of crackles. Arterial oxygen concentrations in patients breathing room air may
be mildly decreased, indicat-ing minimal hypoxemia.
Untreated, PCP eventually progresses and
causes significant pul-monary impairment and, ultimately, respiratory failure.
A few pa-tients have a dramatic onset and fulminant course involving severe
hypoxemia, cyanosis, tachypnea, and altered mental status. Respi-ratory failure
can develop within 2 to 3 days of initial symptoms.
PCP
can be diagnosed definitively by identifying the organ-ism in lung tissue or
bronchial secretions. This is accomplished by such procedures as sputum
induction, bronchial-alveolar lavage, and transbronchial biopsy (by fiberoptic
bronchoscopy).
Mycobacterium avium
com-plex (MAC) disease is a leading OI in people with
AIDS. Or-ganisms belonging to MAC include M.
avium, M. intracellulare, and M.
scrofulaceum. MAC, comprising a group of acid-fast bacilli, usually causes
respiratory infection but is also commonly found in the GI tract, lymph nodes,
and bone marrow. Most patients with AIDS who have T-cell counts less than 100
have widespread disease at diagnosis and are usually debilitated. MAC
infections are associated with rising mortality rates.
Mycobacterium
tuberculosistends to occur in in-jection drug users and
other groups with a preexisting high preva-lence of tuberculosis (TB)
infection. Unlike other OIs, TB tends to occur early in the course of HIV
infection, usually preceding the diagnosis of AIDS. This early occurrence is associated
with the development of caseating granulomas (dry, cheeselike masses of
granulation tissue), which should raise the suspicion of TB. At this stage, TB
responds well to antituberculosis therapy.
TB
that occurs late in HIV infection is characterized by ab-sence of an immune
response to a tuberculin skin test response.
This
is known as anergy and results
because the compromised immune system can no longer respond to the TB antigen.
In the later stages of HIV infection, TB is associated with dissemination to
extrapulmonary sites such as the CNS, bone, pericardium, stomach, peritoneum,
and scrotum. Multiple drug-resistant strains of the bacillus have emerged and
are often associated with non-compliance with antituberculosis therapy.
The GI
manifestations of AIDS include loss of appetite, nausea, vomiting, oral and
esophageal candidiasis, and chronic diarrhea. Diarrhea is a problem in 50% to
90% of all AIDS patients. GI symptoms may be related to the direct effect of
HIV on the cells lining the intestines. Some of the enteric pathogens that
occur most frequently, identified by stool cultures or intestinal biopsy,
include Cryptosporidium muris, Salmonella
species, Isopora belli,Giardia lamblia, CMV, Clostridium difficile, and M. avium-intracellulare. In patients
with AIDS, the effects of diarrhea can bedevastating in terms of profound
weight loss (more than 10% of body weight), fluid and electrolyte imbalances,
perianal skin ex-coriation, weakness, and inability to perform the usual activities
of daily living.
Candidiasis, a fungal infection, occurs in
nearlyall patients with AIDS and AIDS-related conditions. Commonly preceding
other life-threatening infections, it is characterized by creamy-white patches
in the oral cavity. Untreated, oral can-didiasis progresses to involve the
esophagus and stomach. Asso-ciated signs and symptoms include difficult and
painful swallowing and retrosternal pain. Some patients also develop ulcerating
oral lesions and are particularly susceptible to dissemination of can-didiasis
to other body systems.
Wasting syndromeis part of the categoryC case definition for AIDS. Diagnostic criteria
include profound involuntary weight loss exceeding 10% of baseline body weight
and either chronic diarrhea for more than 30 days or chronic weakness and
documented intermittent or constant fever in the absence of any concurrent
illness that could explain these find-ings. This protein-energy malnutrition is
multifactorial. In some AIDS-associated illnesses, patients experience a
hypermetabolic state in which excessive calories are burned and lean body mass
is lost. This state is similar to that seen in sepsis and trauma and can lead
to organ failure. A distinction between cachexia (wasting) and malnutrition or
between cachexia and simple weight loss is important because the metabolic
derangement seen in wasting syndrome may not be modified by nutritional support
alone.
Anorexia, diarrhea, GI malabsorption, and
lack of nutrition in chronic disease all contribute to wasting syndrome.
Progressive tissue wasting, however, may occur with only modest GI involve-ment
and without diarrhea. Tumor necrosis factor (TNF) and interleukin-1 (IL-1) are
cytokines that play important roles in AIDS-related wasting syndrome. Both act
directly on the hypo-thalamus to cause anorexia. Cytokine-induced fever
accelerates the body’s metabolism by 14% for every 1°F increase in temper-ature. TNF causes
inefficient use of lipids by reducing enzymes that are needed for fat
metabolism, whereas IL-1 triggers the re-lease of amino acids from muscle
tissue. People with AIDS gen-erally experience increased protein metabolism in
relation to fat metabolism, which results in significant decreases in lean body
mass due to muscle and protein breakdown.
Hypertriglyceridemia,
seen in people with AIDS and attrib-uted to chronically elevated cytokine
levels, can persist in peoplewith AIDS for months
without tissue wasting and loss of lean body mass. It is believed that
infections and sepsis lead to tran-sient rises in TNF, IL-1, and other cell
mediators above the chronically elevated levels generally seen. These transient
rises in TNF and IL-1 trigger muscle wasting.
Patients
with AIDS have a higher than usual incidence of cancer, possibly related to HIV
stimulation of developing cancer cells or to the immune deficiency allowing
cancer-causing substances, such as viruses, to transform susceptible cells into
malignant cells. Kaposi’s sarcoma, certain types of B-cell lymphomas, and
inva-sive cervical carcinoma are included in the CDC classification of
AIDS-related malignancies. Carcinomas of the skin, stomach, pancreas, rectum,
and bladder also occur more frequently than expected in people with AIDS.
Kaposi’s sarcoma(KS), the most commonHIV-related malignancy, is a disease involving the
endothelial layer of blood and lymphatic vessels. It is associated with human
herpes virus 8 (HHV-8) transmission (USPHS/IDSA, 2002). When first noted in
1872 by Dr. Moritz Kaposi, KS characteris-tically presented as lower-extremity
skin lesions in elderly men of Eastern European ancestry. This form, referred to
as classic Ka-posi’s sarcoma, was slow to progress and easily treated. An
en-demic form of KS, found in children and young men in equatorial Africa, is
more virulent than the classic form. Acquired KS occurs in patients who are
treated with immunosuppressive agents and commonly occurs in patients who have
undergone organ trans-plantation. In such patients, acquired KS usually
resolves once the dose of the immunosuppressive medication is decreased or
discontinued. In people with AIDS, epidemic KS is most often seen in male
homosexuals and bisexuals.
Although the histopathology of all forms of
KS is virtually identical, the clinical manifestations differ: AIDS-related KS
ex-hibits a more variable and aggressive course, ranging from local-ized
cutaneous lesions to disseminated disease involving multiple organ systems.
Cutaneous signs may be the first manifestations of HIV, appearing in more than
90% of HIV-infected patients as immune function deteriorates. These skin signs
correlate to low CD4 counts. Some disorders, such as Kaposi’s sarcoma, oral
hairy leukoplakia, facial molluscum contagiosum, dry skin, and oral
candidiasis, indicate CD4 counts at or below 200 to 300.
Cutaneous lesions appearing anywhere on the
body are usu-ally brownish pink to deep purple. They may be flat or raised and
surrounded by ecchymoses (hemorrhagic patches) and edema (Fig. 52-3). Rapid
development of lesions involving large areas of skin is associated with
extensive disfigurement. The location and size of some lesions can lead to
venous stasis, lymphedema, and pain. Ulcerative lesions disrupt skin integrity
and increase dis-comfort and susceptibility to infection. The most common sites
of visceral involvement include the lymph nodes, GI tract, and lungs.
Involvement of internal organs may eventually lead to organ failure,
hemorrhage, infection, and death.
Diagnosis
of KS is confirmed by biopsy of suspected lesions. Prognosis depends on the
extent of the tumor, presence of con-stitutional symptoms, and CD4 count. Death
may result from tumor progression. More often, however, it results from other
complications of HIV infection.
B-cell lymphomasare the second mostcommon malignancy occurring in people with AIDS. Lym-phomas associated with AIDS usually differ from those occurring in the general population.
Patients with AIDS
are generally much younger than the usual population affected by non-Hodgkin’s
lymphoma. In addition, AIDS-related lymphomas tend to de-velop outside the
lymph nodes, most commonly in the brain, bone marrow, and GI tract. These types
of lymphomas are char-acteristically of a higher grade, indicating aggressive
growth and resistance to treatment. The course of AIDS-related lymphomas
includes multiple sites of organ involvement and complications related to OIs.
Although aggressive combination chemotherapy is frequently successful in
non-Hodgkin’s lymphoma not associ-ated with HIV infection, it is less
successful in people with AIDS because of the severe hematologic toxicity and
complications of OIs that occur from treatment.
An estimated 80% of all patients with AIDS
experience some form of neurologic involvement during the course of HIV
infec-tion. Many neuropathologic disorders are underreported because patients
may have neurologic involvement without overt signs or symptoms. Neurologic
complications involve central, peripheral, and autonomic functions.
Neurologic dysfunction results from the
direct effects of HIV on nervous system tissue, OIs, primary or metastatic
neoplasms, cerebrovascular changes, metabolic encephalopathies, or
compli-cations secondary to therapy. Immune system response to HIV infection in
the CNS includes inflammation, atrophy, demyeli-nation, degeneration, and
necrosis.
HIV encephalopathywas formerly
re-ferred to as AIDS dementia complex. It is a clinical syndrome characterized
by a progressive decline in cognitive, behavioral, and motor functions.
Substantial evidence exists that HIV en-cephalopathy is a direct result of HIV
infection. HIV has been found in the brain and cerebrospinal fluid (CSF) of
patients with HIV encephalopathy. The brain cells infected by HIV are
pre-dominantly the CD4 cells of monocyte-macrophage
lineage. HIV infection is thought to trigger the release of toxins or
lym-phokines that result in cellular dysfunction or interference with
neurotransmitter function rather than cellular damage.
Signs and symptoms may be subtle and
difficult to distinguish from fatigue, depression, or the adverse effects of
treatment for infections and malignancies. Early manifestations include mem-ory
deficits, headache, difficulty concentrating, progressive con-fusion,
psychomotor slowing, apathy, and ataxia. Later stages include global cognitive
impairments, delay in verbal responses, a vacant stare, spastic paraparesis,
hyperreflexia, psychosis, hallu-cinations, tremor, incontinence, seizures,
mutism, and death.
Confirming
the diagnosis of HIV encephalopathy may be dif-ficult. Extensive neurologic
evaluation includes a computed to-mography (CT) scan, which may indicate
diffuse cerebral atrophy and ventricular enlargement. Other tests that may
detect abnor-malities include magnetic resonance imaging (MRI), analysis of CSF
through lumbar puncture, and brain biopsy.
A fungal infection,Cryptococcus
neo-formans, is another common OI among patients with AIDS andcauses
neurologic disease. Cryptococcal meningitis is character-ized by symptoms such
as fever, headache, malaise, stiff neck, nausea, vomiting, mental status
changes, and seizures. Diagnosis is confirmed by CSF analysis.
Progressive multi-focal
leukoencephalopathy is a demyelinating CNS disorder that affects the
oligodendroglia. It occurs in about 3% of AIDS pa-tients. Clinical
manifestations often begin with mental confusion and rapidly progress to
include blindness, aphasia, paresis (slight paralysis), and death. Treatments
have greatly reduced the threat of mortality associated with this disorder.
Other common infections involv-ing the nervous system include Toxoplasma gondii, CMV, and M. tuberculosis. Additional neurologic
manifestations includeboth central and peripheral neuropathies. Vascular
myelopathy is a degenerative disorder affecting the lateral and posterior
columns of the spinal cord, resulting in progressive spastic paraparesis,
ataxia, and incontinence. HIV-related peripheral
neuropathy is thought to be a demyelinating disorder; it is associated with
pain and numbness in the extremities, weakness, diminished deep ten-don
reflexes, orthostatic hypotension, and impotence.
The prevalence of depression among people
with HIV infection is unknown. The causes of depression are multifactorial and
may include a history of preexisting mental illness, neuropsychiatric
disturbances, and psychosocial factors. Depression also occurs in people with
HIV infection in response to the physical symptoms, including pain and weight
loss, and the lack of someone to talk with about their concerns. People with
HIV/AIDS who are de-pressed may experience irrational guilt and shame, loss of
self-esteem, feelings of helplessness and worthlessness, and suicidal ideation.
Cutaneous manifestations are associated with
HIV infection and the accompanying OIs and malignancies. KS (described above)
and OIs such as herpes zoster and herpes simplex are associated with painful
vesicles that disrupt skin integrity. Molluscum
con-tagiosum is a viral infection characterized by deforming
plaqueformation. Seborrheic dermatitis is associated with an indurated,
diffuse, scaly rash involving the scalp and face. Patients with AIDS may also
exhibit a generalized folliculitis associated with dry, flaking skin or atopic
dermatitis, such as eczema or psoriasis. Up to 60% of patients treated with
trimethoprim-sulfamethoxazole (TMP-SMZ) develop a drug-related rash that is
pruritic with pinkish-red
macules and papules. Regardless of the origin of these rashes, patients
experience discomfort and are at increased risk for additional infection from
disrupted skin integrity.
The
endocrine manifestations of HIV infection are not com-pletely understood. At
autopsy, endocrine glands show infiltra-tion and destruction from OIs or
neoplasms. Endocrine function may also be affected by therapeutic agents.
Persistent, recurrent vaginal candidiasis may
be the first sign of HIV infection in women. Past or present genital ulcer
disease is a risk factor for the transmission of HIV infection. Women with HIV
infection are more susceptible to and have increased rates and recurrence of
genital ulcer disease and venereal warts. Ulcer-ative STDs such as chancroid,
syphilis, and herpes are more se-vere in women with HIV infection. Human papillomavirus causes venereal
warts and is a risk factor for cervical intraepithe-lial neoplasia, a cellular
change that is frequently a precursor to cervical cancer. Women with HIV are 10
times more likely to de-velop cervical intraepithelial neoplasia than are those
not infected with HIV. There is a strong association between abnormal Pap
smears and HIV seropositivity. HIV-seropositive women with cervical carcinoma
present with a more advanced stage of disease and have more persistent and
recurrent disease and a shorter in-terval to recurrence and death than women
who do not have HIV infection.
A
significant percentage of women who require hospitalization for pelvic
inflammatory disease (PID) have HIV infection. Women with HIV are at increased
risk for PID, and the inflammation as-sociated with PID may potentiate the
transmission of HIV in-fection. Moreover, women with HIV appear to have a
higher incidence of menstrual abnormalities, including amenorrhea or bleeding
between periods, than women without HIV infection. The failure of health care
providers to consider HIV infection in women may lead to a later diagnosis,
thereby denying women appropriate treatment.
More
than 10% of all AIDS cases in the United States have occurred in people aged 50
years or older. HIV infection in middle-aged and older populations may be
underreported and under-diagnosed because health care professionals erroneously
believe they are not at risk for HIV infection. Many older adults are sexually
active but do not use condoms, viewing them only as a means of unneeded birth
control and not considering themselves at risk for HIV infection. Many older
gay men who grew up and lived in an era when disclosure of their sexual
orientation was not acceptable have lost long-time partners and may turn to
younger males for sexual gratification. Older adults may also be injection drug
users or may have received HIV-infected blood through transfusions before 1985.
As a result, they may be at risk for HIV infection.
Normal age-related changes include a reduction in immune system function similar to that of HIV infection. Older adults are normally at greater risk for infections, cancer, and autoimmune disorders. Many older adults also experience the loss of loved ones, resulting in depression and bereavement, factors that are also associated with depressed immune function. HIV-related de-mentia in the older adult may mimic Alzheimer’s disease and may be misdiagnosed. There are at least three major differences between older (age 50 and up) and younger persons with HIV/ AIDS: presence of comorbidities such as diabetes or high blood pressure; number of persons to whom HIV status was disclosed; and physical functioning ability (Nokes et al., 2000).
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.